Abstract-Major interest surrounds how angiotensin II triggers cardiac hypertrophy via epidermal growth factor receptor transactivation. G protein-mediated transduction, angiotensin type 1 receptor phosphorylation at tyrosine 319, and ␤-arrestin-dependent scaffolding have been suggested, yet the mechanism remains controversial. We examined these pathways in the most reductionist model of cardiomyocyte growth, neonatal ventricular cardiomyocytes. Analysis with [ 32 P]-labeled cardiomyocytes, wild-type and [Y319A] angiotensin type 1 receptor immunoprecipitation and phosphorimaging, phosphopeptide analysis, and antiphosphotyrosine blotting provided no evidence for tyrosine phosphorylation at Y319 or indeed of the receptor, and mutation of Y319 (to A/F) did not prevent either epidermal growth factor receptor transactivation in COS-7 cells or cardiomyocyte hypertrophy. Instead, we demonstrate that transactivation and cardiomyocyte hypertrophy are completely abrogated by loss of G-protein coupling, whereas a constitutively active angiotensin type 1 receptor mutant was sufficient to trigger transactivation and growth in the absence of ligand. These results were supported by the failure of the ␤-arrestin-biased ligand SII angiotensin II to transactivate epidermal growth factor receptor or promote hypertrophy, whereas a ␤-arrestin-uncoupled receptor retained these properties. We also found angiotensin II-mediated cardiomyocyte hypertrophy to be attenuated by a disintegrin and metalloprotease inhibition. Thus, G-protein coupling, and not Y319 phosphorylation or ␤-arrestin scaffolding, is required for epidermal growth factor receptor transactivation and cardiomyocyte hypertrophy via the angiotensin type 1 receptor. A ngiotensin II (Ang II) contributes to progression of left ventricular hypertrophy, a major independent risk factor for myocardial infarction and sudden death, 1 yet the molecular mechanisms governing cardiac hypertrophy remain controversial. Recently, a new paradigm for Ang II hypertrophy has emerged. We and others have shown that angiotensin type 1 receptors (AT 1 Rs) hijack the epidermal growth factor (EFR) receptor (EGFR) via a process termed the "triple membrane-passing signaling paradigm of EGFR transactivation." 2-5 More specifically, AT 1 R activation causes metalloprotease-dependent EGF-like ligand release and subsequent EGFR binding to initiate hypertrophic signaling cascades. Yet the process is likely more complicated: multiple G protein-coupled receptor (GPCR) signals, a disintegrin and metalloproteases (ADAMs), EGF-like ligands, and EGFR subtypes have been implicated in this process. 2 A major focus of Ang II research is the mechanism by which the AT 1 R signals to the EGFR. Recent studies suggested a G protein-independent pathway for growth activation, 6 -9 despite evidence that G␣ q/11 , a heterotrimeric G protein that couples to the AT 1 R, is essential for hypertrophy. 10 Indeed, others indicate that G-protein coupling to AT 1 R is required for EGFR transactivation in COS-7 and vascular smooth muscle cells. [11] [12] [13] Meanwhile, evidence for ␤-arrestin-dependent functional selectivity of the Ang II analog sarcosine, 1 isoleucine, 4 isoleucine, 8 Ang II (SII Ang II), 14 ␤-arrestin-mediated EGFR transactivation by ␤ 1 -adrenoceptors independent of G-protein coupling, 15 and the very recent demonstration of ␤-arrestin-dependent hypertrophy resulting from mechanical stretch 16 suggests that ␤-arrestin scaffolding of extracellular signal-regulated kinase (ERK) 1/2 may contribute to transactivation and/or cardiac hypertrophy.
A ngiotensin II (Ang II) contributes to progression of left ventricular hypertrophy, a major independent risk factor for myocardial infarction and sudden death, 1 yet the molecular mechanisms governing cardiac hypertrophy remain controversial. Recently, a new paradigm for Ang II hypertrophy has emerged. We and others have shown that angiotensin type 1 receptors (AT 1 Rs) hijack the epidermal growth factor (EFR) receptor (EGFR) via a process termed the "triple membrane-passing signaling paradigm of EGFR transactivation." [2] [3] [4] [5] More specifically, AT 1 R activation causes metalloprotease-dependent EGF-like ligand release and subsequent EGFR binding to initiate hypertrophic signaling cascades. Yet the process is likely more complicated: multiple G protein-coupled receptor (GPCR) signals, a disintegrin and metalloproteases (ADAMs), EGF-like ligands, and EGFR subtypes have been implicated in this process. 2 A major focus of Ang II research is the mechanism by which the AT 1 R signals to the EGFR. Recent studies suggested a G protein-independent pathway for growth activation, 6 -9 despite evidence that G␣ q/11 , a heterotrimeric G protein that couples to the AT 1 R, is essential for hypertrophy. 10 Indeed, others indicate that G-protein coupling to AT 1 R is required for EGFR transactivation in COS-7 and vascular smooth muscle cells. [11] [12] [13] Meanwhile, evidence for ␤-arrestin-dependent functional selectivity of the Ang II analog sarcosine, 1 isoleucine, 4 isoleucine, 8 Ang II (SII Ang II), 14 ␤-arrestin-mediated EGFR transactivation by ␤ 1 -adrenoceptors independent of G-protein coupling, 15 and the very recent demonstration of ␤-arrestin-dependent hypertrophy resulting from mechanical stretch 16 suggests that ␤-arrestin scaffolding of extracellular signal-regulated kinase (ERK) 1/2 may contribute to transactivation and/or cardiac hypertrophy.
Given the therapeutic implications of identifying the precise mechanism of Ang II-mediated EGFR transactivation, we investigated the effect of ADAM inhibition and G protein-coupling, ␤-arrestin scaffolding, and Y319 phosphorylation on transactivation in a cell culture model of hypertrophy. Herein, we provide evidence that G-protein coupling, but not Y319 phosphorylation or ␤-arrestin-dependent signaling, is obligatory for EGFR transactivation and AT 1 R-and ADAM-dependent cardiomyocyte hypertrophy.
Materials and Methods cDNA and Adenovirus Constructs
AT 1 R mutants pRc/CMV-[Y215F]AT 1 17 and pRc/CMV-[Y319A] AT 1 8 were generated from rat N-terminal hemagglutinin antigen epitope-tagged AT 1A receptor (pRc/CMV-NHA-AT 1 R) 18 using QuikChange (Stratagene); pRc/CMV-[N111G]AT 1 and the ANP-luc reporter are described. 4, 19 The reporter heparin-binding-epidermal growth factor-alkaline phosphatase (HB-EGF-AP) was from M. Klagsbrun (Children's Hospital Boston, Boston, MA). Adenoviruses were generated as described . 4 [Y319F]AT 1A adenovirus was a generous gift from J. Sadoshima (New Jersey Medical School, Newark, NY). 8 
Cell Culture
Ventricular cardiomyocytes from 1-day-old Sprague-Dawley rats were Percoll purified to Ͼ99% homogeneity, as described. 4 Animals from the Baker Heart Research Institute Precinct Animal Centre were handled in accordance with the Australian Code of Practice for Care and Use of Animals for Scientific Purposes.
COS-7 cells, maintained in DMEM with 10% FBS, were transfected using LipofectAMINE (Invitrogen) and assayed as described. 20 G␣ q/11 inhibitor YM-254890 was a gift from Astellas (Japan).
Hypertrophy Assays
Myocytes were infected 48 hours after plating with purified adenoviruses at multiplicities of infection titrated to give modest expression within the physiological range, assessed by radioligand binding (Table S1 , available in the online Data Supplement at http:// hyper.ahajournals.org). Control green fluorescent protein-expressing adenovirus infected at 300 multiplicities of infection failed to cause hypertrophy (data not shown), demonstrating receptor specificity. After 48 hours, myocytes were stimulated with Ang IIϮin-hibitors; after 72 hours, protein content was assessed (Lowry assay; BioRad) and sarcomeric reorganization was determined by phalloidin staining. 4 
HB-EGF-AP Assay
COS-7 cells were cotransfected with HB-EGF-AP and AT 1 R wildtype (WT) or mutants and replated at 24 hours onto 96-well plates at 60 000 cells per well. The next day, cells were washed twice with PBS and preincubated with inhibitors or PBS. After 45 minutes, cells were stimulated with Ang II (60 minutes), as optimized for maximal HB-EGF-AP media accumulation; 100 L of media were subsequently assayed for alkaline phosphatase activity. 21 
Receptor Phosphorylation
Cardiomyocytes or COS-7 cells were metabolically labeled with [ 32 P] and assayed for AT 1 R phosphorylation, as described. 18 Radiolabeled bands corresponding to the mature or deglycosylated receptor were excised after SDS-PAGE for phosphoamino acid analysis. 22 
Statistical Analyses
Data were analyzed by 1-way ANOVA followed by Dunnett or Bonferroni test for post hoc comparisons, as appropriate. Data are presented as meanϮSEM, where PϽ0.05 was considered significantly different.
Results

Ang II Mediates Neonatal Rat Ventricular Cardiomyocyte Hypertrophy via AT 1 R, EGFR, and Matrix Metalloproteinase/ADAMs
Two models were used in these studies. The first is an extensively characterized 4 neonatal rat ventricular cardiomyocyte (NRVM) model where the AT 1 R is reintroduced by adenoviral infection to recapitulate in vivo levels of expression 23 (the AT 1 R is downregulated during purification 4 ). Isolated NRVMs have been used extensively to delineate signaling preceding cell hypertrophy, 24 and we have found that Ang II-mediated NRVM hypertrophy is entirely dependent on EGFR transactivation. The second model involves COS-7 cells, which have been used extensively by other groups 5, 8, 11, 12 to examine EGFR transactivation because they express high endogenous EGFR but do not express AT 1 R.
In NRVMs infected to express the WT AT 1 R (Table S1 for expression), Ang II (100 nmol/L) stimulated ERK1/2 phosphorylation, which could be blocked by the AT 1 R antagonist candesartan ( Figure 1A ). EGFR transactivation was necessary for both ERK1/2 activation and subsequent NRVM protein accumulation indicative of hypertrophy, because the EGFR inhibitor AG1478 abrogated the effects of Ang II ( Figure 1A and 1B), consistent with our previous characterization of Ang II-mediated transactivation in NRVMs. 4 To assess the triple membrane-passing signaling paradigm mode of transactivation, heparin was used as a nonspecific inhibitor of HB-EGF, and it abolished ERK1/2 phosphorylation and cardiomyocyte hypertrophy ( Figure 1A and 1B) . In COS-7 cells, cotransfection of WT AT 1 R and an HB-EGF-AP enabled examination of the ability of Ang II to stimulate HB-EGF release, an effect that was blocked by the broadspectrum metalloprotease (matrix metalloproteinase) inhibitor GM6001 and was therefore matrix metalloproteinase dependent ( Figure 1C ).
Although AT 1 R can activate 5 and upregulate 25 matrix metalloproteinase activity, the involvement of ADAMs in EGFR transactivation, hypertrophy, and cardiac remodeling remains unproven. In NRVMs, GM6001 and also the ADAM10/17 inhibitor tumor necrosis factor-alpha protease inhibitor-1 (TAPI-1) significantly attenuated Ang II-stimulated growth ( Figure 1D ). We also examined dominantnegative ADAMs 10, 12, and 17 in Ang II-mediated HB-EGF release and hypertrophic growth and found that, whereas each dominant negative inhibited Ang II effects by Ϸ50%, a single ADAM is unlikely to dominate in Ang II-dependent EGFR transactivation and cardiomyocyte hypertrophy ( Figure S1 ).
AT 1 R Is Not Tyrosine Phosphorylated
Tyrosine phosphorylation of the AT 1 R has been both proposed 8,26 -28 or refuted [11] [12] 18, 29 by various groups as a signaling mechanism for the receptor. Therefore, we sought to confirm the phosphorylation profile of the AT 1 R and, more specifically, phosphorylation of tyrosine 319. Y319 was mutated to alanine (Y319A), rendering it incapable of being phosphorylated. Initial studies demonstrated that [Y319A]AT 1 R had equivalent receptor expression, Ang II affinity, and inositol phosphates accumu-lation when compared with WT AT 1 R ( Figure S2 ), indicating that receptor expression, cell surface delivery, ligand binding, and, critically, G-protein coupling were unaffected by mutation at Y319.
Total AT 1 R phosphorylation was determined by analysis of AT 1 R immunopurified from [
32 P]-labeled cardiomyocytes with or without Ang II treatment. [ 32 P] incorporation into the mature AT 1 R was entirely dependent on Ang II stimulation, consistent with previous findings from our own group 18, 19 and others 30, 31 (Figure 2Aii ). The [Y319A]AT 1 R mutant demonstrated similar levels of phosphorylation to the WT receptor in response to Ang II. Furthermore, no tyrosine phosphorylation was detected for either WT or [Y319A]AT 1 Rs by Western blotting (Figure 2Aiii ), despite detection of strong phosphotyrosine blotting for the positive control (EGFstimulated A431 cell extracts, Figure 2Aiv) . To assess the level of tyrosine phosphorylation independent of the sensitivity and specificity of the antiphospho-tyrosine Western blotting, the amino acid specificity of AT 1 R phosphorylation was determined by partial acid hydrolysis of immunopurified AT 1 R from [
32 P]-labeled cardiomyocytes ( Figure 2Bii ). In case the glycosylation state of the receptor-affected hydrolysis, both untreated (normally glycosylated) and deglycosylated samples were analyzed. Strikingly, Ang II-mediated AT 1 R phosphorylation was entirely on serine residues. Critically, there is no Ang II-mediated tyrosine phosphorylation of the AT 1 R. Taken together, these results indicate that the AT 1 R is not phosphorylated at Y319 or any other tyrosine residue on Ang II stimulation in either COS-7 cells or cardiomyocytes, directly in contrast with the findings of Seta and Sadoshima. 8
Y319 Is Not Required for Ang II-Stimulated EGFR Transactivation or NRVM Hypertrophy
Although we found no evidence for Y319 phosphorylation, a recent study found Y319 mutation to suppress cardiac hypertrophy in vivo, 9 despite the indication that Y319 was not required for EGFR transactivation in COS-7 or vascular smooth muscle cells. 11, 32 Thus, we next investigated whether Y319 mutation disrupted EGFR transactivation or NRVM hypertrophy independent of tyrosine phosphorylation. Stimulation of [Y319A]AT 1 R in cardiomyocytes resulted in significant activation of the growth pathway intermediate, ERK1/2, comparable to WT AT 1 R ( Figure 3A and 3B) . Moreover, the EGFR kinase inhibitor AG1478 completely abolished ERK1/2 phosphorylation, demonstrating that [Y319A]AT 1 R-mediated ERK1/2 activation remains entirely dependent on transactivation. This was also the case when the EGFR was overexpressed (data not shown) to recapitulate the experimental conditions of Seta and Sadoshima. 8 To establish whether the triple membrane-passing signaling paradigm pathway, rather than EGFR transactivation overall, was disturbed by [Y319A]AT 1 mutation, COS-7 cells were cotransfected with the HB-EGF-AP reporter and either WT or [Y319A]AT 1 R balanced for expression and stimulated with Ang II. Again, [Y319A]AT 1 still activated the EGFR transactivation pathway, releasing similar levels of HB-EGF to WT ( Figure 3C ). Ang II also stimulated robust EGFRdependent NRVM hypertrophy (32.4Ϯ3.2% above control; Figure 3D ) and sarcomeric reorganization ( Figure 3E ).
[Y319F]AT 1 adenovirus was titrated for equivalent expression (Table S1) , and [Y319F]AT 1 R-expressing myocytes displayed the same sarcomeric reorganization and protein accumulation as WT after Ang II stimulation. Importantly, [Y319F]AT 1 R-mediated hypertrophy remained EGFR dependent ( Figure 3D ). Thus, Y319 mutation to either alanine or phenylalanine had no obvious effect on EGFR transactivation or cardiomyocyte growth.
G-Protein Coupling Is Required for EGFR Transactivation and Hypertrophy
G␣ q/11 is a well-established mediator of cardiac hypertrophy, 10 so we hypothesized that G-protein coupling to the Figure 4A ). 17 [Y215F]AT 1 was confirmed as a G proteinuncoupled mutant with robust expression ( Figure S2 and Table S1 ) and, although [Y215F]AT 1 was described previously with reduced radioligand affinity, we found no statistically significant difference in affinity compared with WT, and the Ang II concentrations used herein are sufficient to ensure almost complete receptor occupancy at either receptor. In COS-7 cells, Ang II failed to cause robust ERK1/2 activation or HB-EGF release via [Y215F]AT 1 R ( Figure 4B and 4C). Furthermore, in [Y215F]AT 1 R-infected NRVMs, Ang II failed to alter total protein or NRVM morphology ( Figure 4D and 4E), despite higher expression than WT (Table S1 ). We confirmed these findings with the G␣ q/11 inhibitor YM-254890 and Ang II analog (SII Ang II) that only activates ␤-arrestin-dependent signaling. 14, 20 In isolated perfused hearts, YM-254890 abrogated Ang II-mediated protein synthesis ( Figure S3) , and YM-254890 pretreatment prevented robust Ang II-mediated ERK1/2 activation, hypertrophy, and ANP-luc induction in WT-expressing NRVMs ( Figure 4F through 4H) . Meanwhile, SII Ang II was unable to promote significant sarcomeric reorganization, NRVM protein changes, or ANP-luc ( Figure 4I through 4K) . In contrast, a truncated AT 1 R (TK325) unable to recruit ␤-arrestins still stimulated hypertrophy and ANP-luc ( Figure 4J and 4K) . Overall, ␤-arrestin signaling appears neither necessary nor sufficient for Ang II-mediated EGFR transactivation (data not shown) and cardiomyocyte hypertrophy.
G-Protein Coupling Is Sufficient for Cardiomyocyte Hypertrophy
A gain-of-function approach was used using [N111G]AT 1 , 19 which is constitutively coupled to G␣ q/11 ( Figure 5A ).
[N111G]AT 1 R-infected NRVMs displayed enhanced basal actin reorganization ( Figure 5B ), whereas ANP-luc was also induced in unstimulated cells ( Figure 5C ). Basal protein accumulation was not changed by increasing WT expression (or other mutants or empty adenovirus; data not shown), whereas [N111G]AT 1 R titration resulted in significant cardiomyocyte hypertrophy ( Figure 5D ). Critically, hypertrophy was prevented by AG1478 ( Figure 5E 22 Each sample was spiked with 1 g of phospho-serine, threonine, and tyrosine to allow positive identification by ninhydrin staining. 22 nϭ2.
coupling to the AT 1 R is sufficient for cardiomyocyte growth and depends on EGFR transactivation.
Discussion
AT 1 R-mediated EGFR transactivation has generated substantial interest, yet the mechanism remains equivocal. The major finding of our study is that G-protein coupling, but not ␤-arrestin-dependent signaling or Y319 phosphorylation, is the mechanism of Ang II-stimulated EGFR transactivation and cardiomyocyte hypertrophy. Furthermore, although our pharmacological inhibitor studies suggest that ADAMs 10, 12, and 17 are involved in NRVM growth, significant redundancy appears to exist among ADAMs in this system. Current theories predict that GPCRs adopt multiple conformations to selectively activate signaling pathways within a cell, known as functional selectivity. 33 Indeed, selectively G protein-uncoupled AT 1 Rs may nevertheless activate markers of growth. 6, 7 These findings were exciting in that they implicated aspects of receptor function, distinct from G-protein coupling, as important growth pathway mediators and suggested that pathway-specific ligands could be developed with greater efficacy and fewer off-target effects. Although surrogate growth markers can be stimulated without G-protein coupling, we report that G-protein coupling is crucial at the cardiomyocyte level for hypertrophy, consistent with a recent study in vascular smooth muscle cells. 13 Moreover, AT 1 R G-protein coupling is sufficient to trigger cardiomyocyte hypertrophy, as seen with [N111G]AT 1A R. This observation is consistent with a recent knock-in study using N111S/⌬329 AT 1 R, which found that mice had significantly larger heart weight/body weight ratios and elevated brain natriuretic peptide levels, although the more profound phenotype was that of hypertension and cardiac fibrosis. 34 Although G␣ q/11 is the obvious candidate for mediating the G protein-dependent effects described herein, it is important to note that other G-protein subunits can be activated by the AT 1 R in both cardiomyocytes and vascular smooth muscle cells. 35 Functional selectivity also describes the ability of ␤-arrestins to act as ligand-regulated scaffolds. 36 Because ␤-arrestin binding precludes catalytic interaction between GPCRs and G proteins, ␤-arrestin binding could be viewed as switching the receptor between two qualitatively, temporally, and spatially distinct signaling modes, G-protein coupled and G-protein uncoupled. Notably, several proteins recruited to GPCR-bound ␤-arrestins are components of growth pathways. 36 Perhaps the best characterized example of ␤-arrestinmediated signaling is SII Ang II at AT 1 Rs. 14 Herein, we used 
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both SII Ang II and [TK325]AT 1 R to demonstrate that ␤-arrestin signaling was neither sufficient nor necessary for transactivation and hypertrophy. Clearly, much remains to be determined with regard to the effects of subcellular trafficking and regulation on signal transduction in the cardiovascular system. Our results diametrically oppose those of Seta and Sadoshima 8 in cells and Zhai et al 9 in mice, because we failed to find evidence of either Y319 phosphorylation or Y319-dependent transactivation and cardiomyocyte hypertrophy. We cannot disregard the possibility that a very low proportion of receptor (below detection by the sensitive experimental techniques used herein) is phosphorylated on Y319, but how this might account for such robust EGFR transactivation by the AT 1 R is difficult to envisage. Indeed, given the notorious difficulties with generating antibodies against the WT AT 1 R, 31 one might predict that a phosphoY319-specific antibody, as used by Sadoshima and colleagues, 8 would be an inefficient tool for immunoprecipitating and detecting the majority of AT 1 Rs in cardiomyocytes. This antibody has not been used in other published studies since the original publication and is not commercially available, so it is difficult to evaluate its selectivity and specificity. Nevertheless, their results comparing cardiac hypertrophy and function in WT and overexpressed Y319F transgenic mice are compelling 9 but possibly reflect more complex interactions between myocytes and other cardiac cells in the hypertrophic process. Instead, our findings agree with two noncardiomyocyte studies: in COS-7, CHO-K1, and vascular smooth muscle cells, neither truncation nor point mutation of Y319 disrupted Ang II-mediated HB-EGF release or EGFR phosphorylation, 11 whereas Shah et al 12 described Ang II-stimulated metalloprotease-dependent EGFR transactivation at both WT and [Y319F]AT 1 Rs. Therefore, regardless of cell type, molecular approach, or transactivation end point assessed, it is unlikely that phosphorylation and recruitment of SHP-2 and EGFR to Y319 are the cardiomyocyte-intrinsic mechanisms of EGFR transactivation. Pressure-induced left ventricular remodeling is known to cause AT 1 R-dependent metalloprotease activation in the heart. 2, 3 Although the responsible metalloprotease(s) is yet to be identified, the ADAM family of proteases are likely mediators, with ADAM17/tumor necrosis factor-alpha converting enzyme the favored candidate. Although our inhibitor studies using GM6001 and TAPI-1 were consistent with this hypothesis, no individual ADAM E/A construct abolished EGFR transactivation, indicating that significant redundancy exists for ADAMs 10, 12, and 17. The multifarious nature of EGFR transactivation remains a significant question.
Perspectives
Cardiac hypertrophy is a major independent risk factor for heart attack and sudden death and presents a significant health burden. Ang II contributes to the development of cardiac hypertrophy in vivo by transactivating the EGFR, and numerous mechanisms have been proposed as therapeutic targets. We have found that the classic pathway of G protein-mediated signal transduction enables AT 1 R-mediated EGFR transactivation, at least in the reductionist in vitro model of NRVMs overexpressing the AT 1 R. The task remains to confirm these findings in whole animals with native receptor expression and for researchers to identify how GPCRs activate ADAMs to liberate EGF-like ligands, a question that has eluded scientists for more than a decade. 
